SPOTLIGHT: Top 20 VC deals of 2007

2007 was another big venture capital year for biotech and medical device companies. Big Pharma's somewhat troubled pipelines contributed significantly to growth in venture investment. Venture capitalists, taking note of Big Pharma's seemingly insatiable appetite for all things biotech, boosted investment by 20 percent over last year, and biopharma and medical device companies raised a record $9.1 billion--almost a third of the total $29.4 billion invested in 2007. While VC funding comes in all shapes and sizes, the biggest deals often indicate which technologies are getting the most attention. Here's a look at the top 20 big winners from 2007. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.